Zeng Z, Yang A, Yang J, Zhang S, Xing Z, Wang X, Mei W, Jiang C, Lin J, Wu X, Xue Y, Wu Z, Yu L, Wang D, Chen J, Zheng S, Lin Q, Chen Q, Dong J, Zheng X, Wang J, Huang J, Chen Z, Chen P, Zheng M, Zhou X, He Y, Lin Y, Chen J. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study. Signal Transduct Target Ther. 2024 Sep 4;9(1):229. doi: 10.1038/s41392-024-01941-x. PMID: 39227388; PMCID: PMC11372099.

The combination of Sintilimab, an anti-PD-1 antibody, with the frontline immunochemotherapy regimen MTR (methotrexate, temozolomide, and rituximab) for primary central nervous system lymphoma (PCNSL) showed a promising response rate and favorable safety profile. These results support our concept of immune-combination therapy to fully activate the anti-cancer immune cycle.